Hepatocellular carcinoma (HCC) remains a leading cause of cancer-related mortality worldwide, particularly in regions with ...

TORONTO--(BUSINESS WIRE)--Alpha Cancer Technologies Inc. (ACT), a biopharmaceutical company focused on developing and commercializing targeted immuno-oncology and immunomodulation therapies based on ...

TORONTO--(BUSINESS WIRE)--Alpha Cancer Technologies Inc. (ACT) a biopharmaceutical company focused on developing and commercializing targeted immuno-oncology and immunology therapies based on its ...

Serum alpha-fetoprotein (AFP) is the current standard of care and only approved biomarker for hepatocellular carcinoma (HCC), used for diagnosis, outcome prediction, long-term follow-up, and treatment ...

Doctors often monitor tumor markers in the blood to help diagnose and treat liver cancer. Alpha-fetoprotein (AFP) is the most common tumor marker that doctors monitor. Tumor markers, also called ...

Hepatocellular carcinoma (HCC) remains a leading cause of cancer-related mortality worldwide, particularly in regions with ...

The US Food and Drug Administration (FDA) has approved ramucirumab (Cyramza, Lilly) as monotherapy for the treatment of patients with hepatocellular carcinoma (HCC) who have an alpha-fetoprotein (AFP) ...